American Society for Artificial Internal Organs

Expansive Clinical Study Finds Improved Outcomes in Heart Transplant Patients Utilizing Paragonix Advanced Organ Preservation

Retrieved on: 
Thursday, September 7, 2023

Paragonix Technologies, Inc ., a leading organ transplant company, announced today the publication of groundbreaking research from a clinical study on patient outcomes following heart transplant surgery.

Key Points: 
  • Paragonix Technologies, Inc ., a leading organ transplant company, announced today the publication of groundbreaking research from a clinical study on patient outcomes following heart transplant surgery.
  • Published in The American Society for Artificial Internal Organs (ASAIO), the study utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database dedicated to donor heart preservation, to analyze post-transplant outcomes and the impact on organ preservation methods on transplant patient health.
  • The US multi-center analysis of GUARDIAN Registry data included 569 adult patients who received heart transplants between October 2015 and January 2022 .
  • “Particularly, in the post-allocation change era, with increasing travel distances and ischemic times, advanced hypothermic organ preservation is an important resource for transplant centers to consider.”
    “The ongoing results of the GUARDIAN-Heart Registry have shown advanced preservation to be a potential game-changer for heart transplant patients.

INNOVATE Corp. Announces Second Quarter 2023 Results

Retrieved on: 
Wednesday, August 9, 2023

WEST PALM BEACH, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the second quarter.

Key Points: 
  • “INNOVATE reported strong second quarter results with revenue of $368.8 million and adjusted EBITDA of $16.5 million, as our operating segments are capitalizing on attractive market opportunities," said Avie Glazer, Chairman of INNOVATE.
  • DBM Global Inc. ("DBMG") reported second quarter 2023 revenue of $362.4 million, a decrease of 5.2%, compared to $382.1 million in the prior year quarter.
  • For the second quarter of 2023, Broadcasting reported revenue of $5.7 million, compared to $9.1 million in the prior year quarter.
  • For the second quarter of 2023, Broadcasting reported Net Loss of $5.3 million compared to $5.7 million in the prior year quarter.

BreathMo®: The New Generation ECMO system Revealed at ASAIO Conference

Retrieved on: 
Saturday, July 22, 2023

Extracorporeal Membrane Oxygenation (ECMO) provides essential support for intensive care unit (ICU) patients, 60% of whom develop heart or respiratory failure with a mortality rate of 23-75%.

Key Points: 
  • Extracorporeal Membrane Oxygenation (ECMO) provides essential support for intensive care unit (ICU) patients, 60% of whom develop heart or respiratory failure with a mortality rate of 23-75%.
  • The limitation of the existing ECMO systems exposed the need for medical device manufacturers to upgrade ECMO devices equipped with advanced functions.
  • BreathMo®, China's homegrown maglev ECMO system that addresses the unmet medical needs of Chinese patients.
  • To bridge clinical gaps in China, magAssist has developed a new generation ECMO system, BreathMo®.

BreathMo®: The New Generation ECMO system Revealed at ASAIO Conference

Retrieved on: 
Friday, July 21, 2023

Extracorporeal Membrane Oxygenation (ECMO) provides essential support for intensive care unit (ICU) patients, 60% of whom develop heart or respiratory failure with a mortality rate of 23-75%.

Key Points: 
  • Extracorporeal Membrane Oxygenation (ECMO) provides essential support for intensive care unit (ICU) patients, 60% of whom develop heart or respiratory failure with a mortality rate of 23-75%.
  • The limitation of the existing ECMO systems exposed the need for medical device manufacturers to upgrade ECMO devices equipped with advanced functions.
  • BreathMo®, China's homegrown maglev ECMO system that addresses the unmet medical needs of Chinese patients.
  • To bridge clinical gaps in China, magAssist has developed a new generation ECMO system, BreathMo®.

By Mimicking Nature, Scientists Build a Better Artificial Lung

Retrieved on: 
Tuesday, May 30, 2023

CAMBRIDGE, Mass., May 30, 2023 /PRNewswire-PRWeb/ -- A mechanical device for oxygenating blood outside the human body, essentially functioning as an artificial lung, is taking a leap forward fifty years after its debut. The original device in clinical use today, called ECMO, which stands for extracorporeal membrane oxygenation, has been reimagined by bioengineers at Draper who took their cues from the way the human body oxygenates blood in the branching circulatory system.

Key Points: 
  • By mimicking blood flow patterns in the human body, engineers improve the safety and efficacy of artificial lungs, a potential benefit to critical care patients and combat casualties.
  • CAMBRIDGE, Mass., May 30, 2023 /PRNewswire-PRWeb/ -- A mechanical device for oxygenating blood outside the human body, essentially functioning as an artificial lung, is taking a leap forward fifty years after its debut.
  • Critical care patients such as premature infants, transplant and pneumonia patients and others suffering respiratory failure and related conditions may benefit, he added.
  • Opinions, interpretations, conclusions, and recommendations contained herein are those of the author(s) and are not necessarily endorsed by the Department of Defense.

Clinical Evidence Shows Reduced Costs and Improved Outcomes in Heart Transplantation

Retrieved on: 
Tuesday, November 22, 2022

The study illustrates the favorable post-operative impact that advanced preservation technology may have on hospital costs and patient outcomes after heart transplant procedures.

Key Points: 
  • The study illustrates the favorable post-operative impact that advanced preservation technology may have on hospital costs and patient outcomes after heart transplant procedures.
  • View the full release here: https://www.businesswire.com/news/home/20221122005269/en/
    Paragonix SherpaPak Cardiac Transport System (CTS) has preserved more than 2,200 hearts since start of clinical use in 2018.
  • The leading FDA cleared and CE marked preservation device for heart transportation, Paragonix SherpaPak CTS provides a sterile, temperature and pressure-controlled environment for organs traveling between operating rooms.
  • In this study, the results indicate that the Paragonix SherpaPak can potentially improve the post-transplant outcomes of patients, leading to lowered overall costs for hospitals.

Draper Advances Growth-Adaptive Pediatric Heart Valve with Sutureless Adhesive

Retrieved on: 
Tuesday, September 27, 2022

CAMBRIDGE, Mass., Sept. 27, 2022 /PRNewswire-PRWeb/ -- Babies born with heart valve defects will have as many as 3 to 5 open heart surgeries before adulthood to replace prosthetics as they grow. Mortality and morbidity remain high, in part because there is no clinical standard for valve replacement in children under 5 years of age.

Key Points: 
  • A sutureless adhesive applied to a pediatric heart valve stent may save surgeons time during operations and simplify the production process for device manufacturers.
  • CAMBRIDGE, Mass., Sept. 27, 2022 /PRNewswire-PRWeb/ -- Babies born with heart valve defects will have as many as 3 to 5 open heart surgeries before adulthood to replace prosthetics as they grow.
  • To address this need, Draper engineers are developing the Low-force Expanding/Adaptable Pediatric (LEAP) Valvethe first heart valve that can grow with the patient.
  • The LEAP heart valve will incorporate the microstructures we are developing to integrate mechanically with the bioprosthetic valve tissue without the need for sutures."

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

Retrieved on: 
Monday, June 14, 2021

The results were presented at the American Society for Artificial Internal Organs (ASAIO) Annual Meeting on June 12th, 2021, in Washington, DC, by Carl Botterbusch, CTO of CorWave.

Key Points: 
  • The results were presented at the American Society for Artificial Internal Organs (ASAIO) Annual Meeting on June 12th, 2021, in Washington, DC, by Carl Botterbusch, CTO of CorWave.
  • The results of the 90-day in vivo study were reported during an oral presentation entitled "Design Optimization of the CorWave Membrane LVAD."
  • These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.
  • Throughout the study, the device provided pulsatile blood flow, synchronized with the native heart, without the use of sensors.

American Society For Artificial Internal Organs (ASAIO) Outlines Best Practices For Advanced Pulmonary And Cardiac Support Of COVID-19 Patients

Retrieved on: 
Monday, May 4, 2020

TUCSON, Ariz., May 4, 2020 /PRNewswire/ -- The American Society for Artificial Internal Organs (ASAIO) has outlined best practices for advanced pulmonary and cardiac support of COVID-19 patients in a paper entitled "Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations from ASAIO A Living Working Document" being published this month in the ASAIO Journal and Circulation: Heart Failure , a journal of the American Heart Association.

Key Points: 
  • TUCSON, Ariz., May 4, 2020 /PRNewswire/ -- The American Society for Artificial Internal Organs (ASAIO) has outlined best practices for advanced pulmonary and cardiac support of COVID-19 patients in a paper entitled "Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations from ASAIO A Living Working Document" being published this month in the ASAIO Journal and Circulation: Heart Failure , a journal of the American Heart Association.
  • "An advanced treatment method known as ECMO extracorporeal membrane oxygenation is the best lifesaving technology we have today," he continued.
  • He convened a group of leading international cardiac, cardiac surgical, and pulmonary specialists to compile the recommendations outlined in the paper.
  • The American Society for Artificial Internal Organs (ASAIO)has been in existence for close to 70 years, striving to save lives one medical device at a time.

SpecialtyCare Medical Department Collaborates with The American Society for Artificial Organs (ASAIO) on Research to Understand the Role of ECMO in the Management of COVID-19

Retrieved on: 
Friday, April 24, 2020

Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, medications, and short-term outcomes through hospital discharge.

Key Points: 
  • Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, medications, and short-term outcomes through hospital discharge.
  • SpecialtyCare CEO, Sam Weinstein, MD, MBA, said, We are honored to collaborate with ASAIO to share crucial information on this potentially life-saving therapy.
  • More than 1,100 hospitals and 13,500 physicians trust SpecialtyCare to help them achieve exceptional care outcomes, regulatory compliance, and financial results.
  • The American Society for Artificial Internal Organs (ASAIO) has been in existence for close to 70 years, striving to save lives one medical device at a time.